Why is 2026 already a record year for M&A activity?

Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP makes the difference.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

14 July 2026 An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.

Regulation & Industry

Ashurst Perkins Coie opens its doors following landmark merger

29 June 2026 The newly combined transatlantic firm brings together more than 950 partners across 20 countries, uniting leading patent, trade secrets, life sciences, and tech practices.

Regulation & Industry

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

More features

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

Why is 2026 already a record year for M&A activity?

More on this story

Editor's picks

Editor's picks

More features